Ambry
TD Cowen Reinstates Buy Rating for Tempus AI, Raises Price Target to $74
The bank had suspended its rating and price target for Tempus during its $600 million acquisition of Ambry Genetics due to TD Securities' involvement in the deal.
Ambry Updates Hereditary Cancer Risk Panels With Eye Toward Gene-Disease Validity, Guidelines
Premium
The panels assess genes with strong disease links and clinical management guidelines, but the firm offers limited-evidence genes as an add-on option.
Top Five Articles on 360Dx Last Week: Tempus Buy of Ambry Genetics; Blood-Based MRD Testing; More
Last week, readers were most interested in a story about Tempus' expectations for its acquisition of cancer testing firm Ambry.
The firm's Q3 2024 revenues rose 33 percent year over year as both its genomics and data and services revenues increased in the double-digit percent range.
Labs, Doctors Still Grapple With Patient Recontact Despite Streamlined Variant Reclassification
Premium
Although leading labs have coalesced around the value of protocols for making sure updated variant calls get to patients, strategies still vary and practical challenges remain.